VICODIN TUSS® Expectorant Syrup contains hydrocodone bitartrate, semi-synthetic centrally-acting narcotic antitussive and guaifenesin, an expectorant for oral administration.

Each teaspoonful (5 mL) contains:

Hydrocodone bitartrate USP ...................... 5 mg
Guaifenesin USP .................................... 100 mg

VICODIN TUSS Expectorant Syrup also contains: glycerin, L-menthol, methylparaben, propylparaben, propylene glycol, sodium saccharin, sorbitol solution, artificial flavoring, and purified water.

Clinical trials have proven hydrocodone bitartrate to be an effective antitussive agent which is pharmacologically 2 to 8 times as potent as codeine. At equi-effective doses, its sedative action is greater than codeine. The precise mechanism of action of hydrocodone and other opiates is not known, however, hydrocodone is believed to act by directly depressing the cough center. In excessive doses hydrocodone, like other opium derivatives, can depress respiration. The effects of hydrocodone in therapeutic doses on the cardiovascular system is insignificant. The constipation effects of hydrocodone are much weaker than that of morphine and no stronger than that of codeine. Hydrocodone can produce miosis, euphoria, physical and psychological dependence. At therapeutic antitussive doses, it does exert analgesic effects. Following a 10 mg oral dose of hydrocodone administered to five male human subjects the mean peak concentration was 23.6 ± 5.2 ng/mL. Maximum serum levels were achieved at 1.3 ± 0.3 hours and half-life was determined to be 3.8 ± 0.3 hours. Hydrocodone exhibits a complex pattern of metabolism including O-demethylation, N-demethylation and 6-ketoreduction to the corresponding 6-(alpha)- and 6-(beta)-hydroxymetabolites.

The exact mechanism of action is not established but guaifenesin is believed to act by stimulating receptors in the gastric mucosa that initates a reflex secretion of respiratory tract fluid, thereby increasing the volume and decreasing the viscosity of bronchial secretions. Studies with guaifenesin indicate that it is rapidly absorbed from the gastrointestinal tract and has a half-life of one hour.

VICODIN TUSS Expectorant is indicated for the symptomatic relief of irritating non-productive cough associated with upper and lower respiratory tract congestion.


VICODIN TUSS Expectorant is contraindicated in patients hypersensitive to hydrocodone or guaifenesin. Patients known to be hypersensitive to other opioids may exhibit cross sensitivity to hydrocodone.

Hydrocodone can produce drug dependence of the morphine type and therefore has the potential for being abused. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of VICODIN TUSS Expectorant and it should be prescribed and administered with the same degree of caution appropriate to the use of other narcotic drugs (see DRUG ABUSE AND DEPENDENCE ).

Respiratory Depression: VICODIN TUSS Expectorant produces dose-related respiratory depression by directly acting on the brain stem respiratory centers. If respiratory depression occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated.

Head Injury and Increased Intracranial Pressure: The respiratory depressant properties of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.

Acute Abdominal Conditions: The administration of VICODIN TUSS Expectorant or other opioids may obscure the diagnosis or clinical course of patients with acute abdominal conditions.


Before prescribing medication to suppress or modify cough, it is important to ascertain that the underlying cause of cough is identified, that modification of cough does not increase the risk of clinical or physiologic complications, and that appropriate therapy for the primary disease is provided.

Usage in Ambulatory Patients:   Hydrocodone, like all narcotics, may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery, and patients should be warned accordingly.

Drug Interactions:   Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative hypnotics or other CNS depressants (including alcohol) concomitantly with hydrocodone may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced (see ).

Laboratory Interactions:   The metabolite of guaifenesin has been found to produce an apparent increase in urinary 5-hydroxyindoleacetic acid, and guaifenesin therefore may interfere with the interpretation of this test for the diagnosis of carcinoid syndrome. Guaifenesin administration should be discontinued 24 hours prior to the collection of urine specimens for the determination of 5-hydroxyindoleacetic acid.

Carcinogenesis, mutagenesis, impairment of fertility: Carcinogenicity, mutagenicity and reproduction studies have not been conducted with VICODIN TUSS® Expectorant.

Usage in Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with VICODIN TUSS Expectorant. It is also not known whether VICODIN TUSS Expectorant can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.

VICODIN TUSS Expectorant should be given to a pregnant woman only if clearly needed.

Nonteratogenic effects:   Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal. Chlorpromazine 0.7-1.0 mg/kg q 6 h, phenobarbital 2 mg/kg q 6 h, and paregoric 2-4 drops/kg q 4 h, have been used to treat withdrawal symptoms in infants. The duration of therapy is 4 to 28 days, with the dosages decreased as tolerated.

Nursing mothers:   It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from VICODIN TUSS Expectorant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Geriatric Use:   Clinical studies of VICODIN TUSS did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.


Respiratory System: Hydrocodone produces dose-related respiratory depression by acting directly on brain stem respiratory centers.

Cardiovascular System: Hypertension, postural hypotension and palpitations.

Genitourinary System: Ureteral spasm, spasm of vesical sphincters and urinary retention have been reported with opiates.

Central Nervous System: Sedation, drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, dizziness, psychic dependence, mood changes and blurred vision.

Gastrointestinal System: Nausea and vomiting occur more frequently in ambulatory than in recumbent patients.


Special care should be exercised in prescribing hydrocodone for emotionally unstable patients and for those with a history of drug misuse. Such patients should be closely supervised when long-term therapy is contemplated.

VICODIN TUSS® Expectorant is a Schedule III narcotic. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of narcotics; therefore, VICODIN TUSS Expectorant should always be prescribed and administered with caution. Physical dependence is the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome.

Patients physically dependent on opioids will develop an abstinence syndrome upon abrupt discontinuation of the opioid or following the administration of a narcotic antagonist. The character and severity of the withdrawal symptoms are related to the degree of physical dependence. Manifestations of opioid withdrawal are similar to but milder than that of morphine and include lacrimation, rhinorrhea, yawning, sweating, restlessness, dilated pupils, anorexia, goose-flesh, irritability and tremor. In more severe forms, nausea, vomiting, intestinal spasm and diarrhea, increased heart rate and blood pressure, chills, and pains in bones and muscles of the back and extremities may occur. Peak effects will usually be apparent at 48 to 72 hours.

Treatment of withdrawal is usually managed by providing sufficient quantities of an opioid to suppress severe withdrawal symptoms and then gradually reducing the dose of opioid over a period of several days.


Signs and Symptoms:   Serious overdosage with VICODIN TUSS Expectorant is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage apnea, circulatory collapse, cardiac arrest, and death may occur.

Treatment:   Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote for respiratory depression which may result from overdosage or unusual sensitivity to narcotics including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant respiratory depression. Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug. Activated charcoal may be of benefit.


Usual Adult Dose: One teaspoonful (5 mL) after meals and at bedtime, not less than 4 hours apart (not to exceed 6 teaspoonsful in a 24 hour period). Treatment should be initiated with one teaspoonful and subsequent doses, up to a maximum single dose of 3 teaspoonsful, adjusted if required.

Usual Children's Dose:

Over 12 years: Initial dose 1 teaspoonful; maximum single dose, 2 teaspoonsful.

6 to 12 years: Initial dose 1 / 2 teaspoonful; maximum single dose, 1 teaspoonful.


VICODIN TUSS® Expectorant is available in bottles as a colorless, cherry-flavored syrup which contains no sugar, alcohol or dye.

One pint: NDC 0044-0730-16.

Store in a tight, light resistant container as defined in the USP. Keep tightly closed.

Storage: Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature].

©2000 Knoll Pharmaceutical Company

VICODIN TUSS is a registered trademark of Knoll Pharmaceutical Company

All rights reserved

A Schedule CIII Narcotic. Oral prescription where permitted by State Law.

Revised: May 2000

Knoll Laboratories

A Division of

Knoll Pharmaceutical Company

Mt. Olive, NJ 07828

BASF Pharma                                             0900007-3


NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.

The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected overdosage, the drug' identity should be verified by chemical analysis.